Thyroid Eye Disease Ted clinical trials

Explore recruiting thyroid eye disease ted clinical trials.

Recruiting thyroid eye disease ted studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thyroid Eye Disease Ted trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease

Estonia, Czechia, Germany, Spain, Greece, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Spain, Germany, France, Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

VRDN-003-302: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)

Germany, Spain, Hungary, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

VRDN-003-301: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)

Hungary, Spain, Poland, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Italy, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

Slovakia, Hungary, Belgium, Italy, Latvia, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Thyroid Eye Disease Ted trials by city

Thyroid Eye Disease Ted in Toronto Thyroid Eye Disease Ted in Vancouver Thyroid Eye Disease Ted in Montreal Thyroid Eye Disease Ted in Calgary Thyroid Eye Disease Ted in Edmonton Thyroid Eye Disease Ted in Ottawa Thyroid Eye Disease Ted in Winnipeg Thyroid Eye Disease Ted in Quebec City Thyroid Eye Disease Ted in Hamilton Thyroid Eye Disease Ted in Kitchener Thyroid Eye Disease Ted in London Thyroid Eye Disease Ted in Halifax Thyroid Eye Disease Ted in New York Thyroid Eye Disease Ted in Los Angeles Thyroid Eye Disease Ted in Chicago Thyroid Eye Disease Ted in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease